GLENMARK PHARMACEUTICALS Financial Statement Analysis
|
||
|
The Revenues of GLENMARK PHARMACEUTICALS have increased by 1.98% YoY .
The Earnings Per Share (EPS) of GLENMARK PHARMACEUTICALS has increased by Positive YoY. |
||
GLENMARK PHARMACEUTICALS Last 5 Annual Financial Results
[BOM: 532296|NSE : GLENMARK]
| Consolidated | Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 |
|---|---|---|---|---|---|
| Revenues | ₹11,813 Cr | ₹11,583 Cr | ₹12,305 Cr | ₹10,944 Cr | ₹10,641 Cr |
| Expenses | ₹10,618 Cr | ₹9,948 Cr | ₹9,985 Cr | ₹8,860 Cr | ₹8,943 Cr |
| Operating Profit (Excl OI) | ₹1,195 Cr | ₹1,635 Cr | ₹2,320 Cr | ₹2,084 Cr | ₹1,698 Cr |
| Other Income | ₹840 Cr | ₹289 Cr | ₹167 Cr | ₹50 Cr | ₹160 Cr |
| Interest | ₹516 Cr | ₹349 Cr | ₹298 Cr | ₹353 Cr | ₹377 Cr |
| Depreciation | ₹582 Cr | ₹569 Cr | ₹487 Cr | ₹444 Cr | ₹417 Cr |
| Profit Before Tax | ₹36 Cr | ₹240 Cr | ₹1,441 Cr | ₹1,382 Cr | ₹1,096 Cr |
| Profit After Tax | ₹-1,831 Cr | ₹-90 Cr | ₹994 Cr | ₹970 Cr | ₹776 Cr |
| Consolidated Net Profit | ₹-1,502 Cr | ₹297 Cr | ₹942 Cr | ₹970 Cr | ₹776 Cr |
| Earnings Per Share (Rs) | ₹37.11 | ₹-53.21 | ₹10.53 | ₹33.37 | ₹34.38 |
| PAT Margin (%) | 3.57 | -6.61 | -0.32 | 3.57 | 3.84 |
| ROE(%) | 12.56 | -21.18 | -0.97 | 12.33 | 14.81 |
| ROCE(%) | 16.16 | 4.88 | 4.43 | 14.19 | 15.30 |
| Total Debt/Equity(x) | 0.25 | 0.13 | 0.46 | 0.40 | 0.67 |
Key Financials |
||
| Market Cap | : | ₹ 66,047.5 Cr |
| Revenue (TTM) | : | ₹ 16,468.1 Cr |
| Net Profit(TTM) | : | ₹ 1,065.0 Cr |
| EPS (TTM) | : | ₹ 37.7 |
| P/E (TTM) | : | 62.0 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| GLENMARK PHARMACEUTICALS | 3.8% | 4% | 64.1% |
| SUN PHARMACEUTICAL INDUSTRIES | 3.2% | 12.5% | 10.6% |
| DIVIS LABORATORIES | 2.9% | 8.5% | 11.4% |
| CIPLA | 10.4% | 15.9% | -5.8% |
| TORRENT PHARMACEUTICALS | 0.3% | 5.7% | 36.3% |
| DR REDDYS LABORATORIES | 4.8% | 9% | 10.8% |
| MANKIND PHARMA | 5% | 18.6% | -1.7% |
| ZYDUS LIFESCIENCES | 6.5% | 5.5% | 12.2% |
| LUPIN | 0.3% | -3.2% | 10.2% |
GLENMARK PHARMACEUTICALS Revenues
[BOM: 532296|NSE : GLENMARK]
| Y-o-Y | 1.98 % |
| 5 Yr CAGR | 2.65 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2025 | ₹11,813 Cr | 1.98 | |
| Mar2024 | ₹11,583 Cr | -5.86 | |
| Mar2023 | ₹12,305 Cr | 12.44 | |
| Mar2022 | ₹10,944 Cr | 2.85 | |
| Mar2021 | ₹10,641 Cr | - | |
GLENMARK PHARMACEUTICALS Operating Profit
[BOM: 532296|NSE : GLENMARK]
| Y-o-Y | -26.89 % |
| 5 Yr CAGR | -8.40 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2025 | ₹1,195 Cr | -26.89 | |
| Mar2024 | ₹1,635 Cr | -29.53 | |
| Mar2023 | ₹2,320 Cr | 11.32 | |
| Mar2022 | ₹2,084 Cr | 22.75 | |
| Mar2021 | ₹1,698 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | -28.33 % |
| 5 Yr CAGR | -10.76 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2025 | 10.12% | -28.33 | |
| Mar2024 | 14.12% | -25.13 | |
| Mar2023 | 18.86% | -1.00 | |
| Mar2022 | 19.05% | 19.36 | |
| Mar2021 | 15.96% | - | |
GLENMARK PHARMACEUTICALS Profit After Tax
[BOM: 532296|NSE : GLENMARK]
| Y-o-Y | Negative |
| 5 Yr CAGR | Negative |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2025 | ₹-1,502 Cr | Negative | |
| Mar2024 | ₹297 Cr | -68.44 | |
| Mar2023 | ₹942 Cr | -2.92 | |
| Mar2022 | ₹970 Cr | 25.01 | |
| Mar2021 | ₹776 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | Positive |
| 5 Yr CAGR | -1.81 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2025 | 3.57 % | Positive | |
| Mar2024 | -6.61 % | Negative | |
| Mar2023 | -0.32 % | Negative | |
| Mar2022 | 3.57 % | -7.03 | |
| Mar2021 | 3.84 % | - | |
GLENMARK PHARMACEUTICALS Earnings Per Share (EPS)
[BOM: 532296|NSE : GLENMARK]
| Y-o-Y | Positive |
| 5 Yr CAGR | 1.93 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2025 | ₹37 | Positive | |
| Mar2024 | ₹-53 | Negative | |
| Mar2023 | ₹11 | -68.44 | |
| Mar2022 | ₹33 | -2.94 | |
| Mar2021 | ₹34 | - | |
GLENMARK PHARMACEUTICALS Return on Capital Employed (ROCE)
[BOM: 532296|NSE : GLENMARK]
| Y-o-Y | 231.15 % |
| 5 Yr CAGR | 1.38 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2025 | 16.16% | 231.15 | |
| Mar2024 | 4.88% | 10.16 | |
| Mar2023 | 4.43% | -68.78 | |
| Mar2022 | 14.19% | -7.25 | |
| Mar2021 | 15.3% | - | |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
| Current Share Price | : | ₹2,340.5 |
| Current MarketCap | : | ₹ 66,047.5 Cr |
| Updated EOD on | : | May 18,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLENMARK PHARMACEUTICALS | 3.8% |
4% |
64.1% |
| SENSEX | -0.9% |
-3.6% |
-8.6% |
GLENMARK PHARMACEUTICALS related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE ALLCAP | 6.4% | 8.9% | 7.5% |
| BSE MIDSMALLCAP | 4.7% | 9% | 8.4% |
| BSE LARGEMIDCAP | 4.5% | 7.2% | 8.3% |
| BSE 500 SHARIAH | 4.3% | 4.3% | 1.1% |
| BSE HEALTHCARE | 1% | 9.4% | 13.7% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY PHARMA | 2.5% | 10.4% | 17.3% |
| NIFTY HEALTHCARE INDEX | 1.9% | 9.4% | 14.7% |
| NIFTY MIDSMALL HEALTHCARE | 0.2% | 9.3% | 17.9% |
| NIFTY 200 | -1.1% | -1% | -1.2% |
| NIFTY200 ALPHA 30 | -1.2% | 1% | 6.4% |
You may also like the below Video Courses
FAQ about GLENMARK PHARMACEUTICALS Financials
How the annual revenues of GLENMARK PHARMACEUTICALS have changed ?
The Revenues of GLENMARK PHARMACEUTICALS have increased by 1.98% YoY .
How the Earnings per Share (EPS) of GLENMARK PHARMACEUTICALS have changed?
The Earnings Per Share (EPS) of GLENMARK PHARMACEUTICALS has increased by Positive YoY .
Check out Intrinsic Value of Peers of GLENMARK PHARMACEUTICALS
Compare Stock Analytics of Peers of GLENMARK PHARMACEUTICALS
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs CIPLA LTD
TORRENT PHARMACEUTICALS LTD vs DR REDDYS LABORATORIES LTD vs
